CARDIUM THERAPEUTICS, INC

Cardium Presents New Generx Findings at 2012 Annual Gene and Cell Therapy Forum

Biotechnology Industry on the Upswing - BioSante and Cardium Therapeutics Look to Rally

Cardium Therapeutics regains listing compliance with NYSE Amex

Cardium Regains Listing Compliance With NYSE Amex

Cardium Announces First International Marketing And Distribution Agreement For Commercialization Of Excellagen? In South Korea

Cardium: 1st int'l marketing, distribution agreement for Excellage in So. Korea

Cardium Announces First International Marketing and Distribution Agreement for Commercialization of Excellagen™ in South Korea

Cardium to Present at Upcoming Investor Conferences

Cardium reports on renewed compliance with NYSE Amex listing guidelines

Cardium Reports on Renewed Compliance With NYSE Amex Exchange Listing Guidelines

Cardium Therapeutics (CXM) Enters Into Cross-Strategic Equity Investment Partnership with SourceOne Global Partners

Cardium Therapeutics enters cross-strategic equity investment with SourceOne

Cardium and SourceOne Global Partners Enter Into Cross-Strategic Equity Investment with Plans to Jointly Develop Nutritional Supplements and Medical Foods

Cardium Announces MedPodium Neo-Energy™ and Neo-Carb Bloc™

Cardium Therapeutics and Celsion Corporation - Low Valuations Spark Investor Enthusiasm

Cardium Presents Third Quarter 2011 Financial Results and Reports on Near-Term Milestones

Faster FDA Drug Reviews Should Benefit Cardium Therapeutics and CytRx Corporation

Faster FDA Drug Reviews Should Benefit Cardium Therapeutics and CytRx Corporation

Atherosclerosis or Coronary Artery Disease Therapeutics (CAD) - Pipeline Assessment and Market Forecasts to 2018

Cardium Therapeutics and Oncothyreon Poised for Growth

Cardium announces FDA 510 clearance for U.S. marketing, sale of Excellagen

Cardium Announces FDA 510(k) Clearance for U.S. Marketing and Sale of Excellagen Formulated Collagen Topical Gel for Diabetic Foot Ulcers, Pressure Ulcers and Other Dermal Wounds

Cardium Therapeutics'c ompliance plan accepted by NYSE Amex

Cardium Reports Exchange Compliance Plan Accepted by NYSE Amex

Cardium to Present at the Rodman & Renshaw Annual Healthcare Investment Conference

Cardium Therapeutics updates on exchange listing and related business matters

Cardium Provides Update on Exchange Listing and Related Business Matters

Cardium to Present at Southern California Investor Conference

Cardium Announces Market Introduction of New D-Sorb™ to Expand the MedPodium Healthy Lifestyle Product Line

Cardium Therapeutics receives final $1.1M from Philips' Innercool acquisition

Cardium Announces Receipt of $1.1 Million in Funds from Philips' Acquisition of Innercool Therapies

Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones

Cardium Therapeutics reports on Excellagen news

Cardium Provides Update on Excellagen 510(K) Registration and Commercialization Plans

Cardium Therapeutics reports on Transdel transaction

Cardium Reports on Transdel Transaction

Cardium Announces Market Introduction of New Alena™ Clinical Strength Carb Blocker to Expand the MedPodium Healthy Lifestyle Product Line

Transdel Pharmaceuticals, Inc. Files for Chapter 11, Agrees to Sell Lead Drug Candidate to Cardium Therapeutics, Inc.

Cardium Therapeutics acquires Transdel's business assets for up to $4M

Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets